Jefferies analyst David Steinberg says the "real story" in Perrigo's earnings report is not the better than expected Q4 results but the FY17 guidance, which he notes disappointed even after "sharp cuts" to Street estimates just four weeks ago. For the first time in memory, both the company's revenue and earnings will decline, Steinberg tells investors in post-earnings research note. This is "not a good story line for an OTC-focused company," the analyst adds. Steinberg slightly raised his price target for Perrigo to $71 and keeps a Hold rating on the shares.